<DOC>
	<DOC>NCT01684865</DOC>
	<brief_summary>This prospective observational study will evaluate the safety and efficacy of first-line rituximab maintenance therapy in participants with follicular non-Hodgkin's lymphoma. Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will be followed for a maximum of 3 years or until disease progression occurs.</brief_summary>
	<brief_title>An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histological diagnosis of follicular nonHodgkin's lymphoma Complete or partial response to firstline induction therapy with chemotherapy with rituximab Participants about to receive firstline rituximab maintenance treatment for follicular nonHodgkin's lymphoma according to the local label Pregnant or lactating women Receipt of an investigational drug within 30 days prior to initiation of observational drug Any medical or psychological alteration that, to criterion of the investigator, can jeopardize the capacity of the participant to grant informed consent Central nervous system involvement Hepatitis B or C virus infection or human immuno deficiency infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>